Fasting Insulin: The Most Underordered Metabolic Test in Australia

Disclaimer: This article is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any health-related decisions based on blood test results.

---

Fasting glucose is on virtually every GP-ordered metabolic panel in Australia. HbA1c is ordered routinely for anyone with diabetes risk factors. Fasting insulin is ordered almost never — and that omission is costing people a decade of early intervention.

The reason fasting insulin matters is structural: glucose is a lagging indicator. The body defends blood sugar aggressively, and for years — sometimes more than a decade — it will succeed. Insulin resistance develops silently while the pancreas compensates by producing ever-larger quantities of insulin. Fasting glucose sits in the normal range. HbA1c looks fine. The standard metabolic panel returns no flags.

Meanwhile, the chronically elevated insulin is doing damage: driving atherogenic dyslipidaemia, promoting visceral fat deposition, suppressing sex hormone-binding globulin, and pushing the liver toward fatty infiltration. By the time glucose finally climbs, significant metabolic harm has already occurred.

Fasting insulin catches this earlier than any other routine blood test. It is also one of the cheapest and most technically straightforward assays available. The barrier is not scientific — it is the habits of the medical system.

---

What Fasting Insulin Measures

Insulin is a peptide hormone secreted by pancreatic beta cells in response to rising blood glucose. Its primary role is to signal tissues — liver, muscle, and adipose — to take up glucose from circulation and either use it for energy or store it as glycogen or fat.

A fasting insulin measurement captures basal insulin secretion after an overnight fast, when blood glucose is at its daily nadir and insulin demand should be at its lowest. In a person with good insulin sensitivity, a small amount of insulin is sufficient to maintain stable fasting glucose. The number should be low.

When insulin sensitivity declines — as it does in metabolic syndrome, visceral obesity, physical inactivity, poor sleep, and high refined-carbohydrate intake — tissues become less responsive to insulin signalling. The pancreas compensates by secreting more. Fasting insulin rises even as glucose holds steady.

This is the compensated phase of insulin resistance. It can persist for a decade or more before beta cell capacity becomes exhausted and glucose begins to climb. During this entire window, fasting insulin is elevated. Fasting glucose is not. The person receives a clean bill of metabolic health.

Fasting insulin testing closes this diagnostic gap.

---

Why Glucose and HbA1c Are Not Enough

Fasting Glucose

Fasting glucose (<6.0 mmol/L is the conventional normal range in Australia) measures blood sugar concentration after an overnight fast. It is a snapshot of a single moment. Because the body regulates blood glucose tightly through multiple counter-regulatory mechanisms, glucose will remain within the normal range throughout the early-to-middle stages of insulin resistance.

A fasting glucose of 5.4 mmol/L is indistinguishable between someone with pristine insulin sensitivity and someone who is severely insulin resistant but whose pancreas is working double-time to compensate. Fasting insulin separates them immediately.

HbA1c

HbA1c reflects the average blood glucose concentration over the preceding 8–12 weeks, expressed as a percentage of glycated haemoglobin. It is an excellent marker of established glycaemic control and is central to diabetes management. As a screening tool for early metabolic dysfunction, it has the same fundamental limitation as fasting glucose — it does not move until the compensatory phase has broken down and glucose is genuinely elevated.

A HbA1c of 5.4% in someone with a fasting insulin of 18 mIU/L tells two very different stories depending on which number you look at. HbA1c says: currently normal. Fasting insulin says: the system is under severe strain.

The Three-Test Picture

The most informative approach pairs all three:

| Test | What it reveals | When it becomes abnormal | |---|---|---| | Fasting insulin | Beta cell compensation; insulin resistance severity | Early — rises during compensated insulin resistance | | Fasting glucose | Blood sugar regulation | Mid-to-late — rises when compensation begins to fail | | HbA1c | Sustained glycaemic burden over weeks | Late — moves only when glucose is chronically elevated |

Ordering only fasting glucose or HbA1c without fasting insulin is like monitoring tyre pressure by watching for a flat. Technically accurate at the moment of catastrophe, useless during the long degradation that precedes it.

---

Optimal Fasting Insulin Ranges

This is where standard laboratory reference ranges become actively misleading.

Most Australian pathology providers report fasting insulin with a reference range of approximately <25 mIU/L. This is a population-derived cut-off — it describes the upper bound of the range seen in a broad population sample, not an optimal metabolic state. A fasting insulin of 22 mIU/L falls within "normal" by this standard. It represents significant insulin resistance by any functional medicine or longevity medicine criterion.

Functional Medicine and Longevity Targets

Research and functional medicine literature consistently uses narrower targets that reflect genuine metabolic health rather than population norms:

| Fasting Insulin | Interpretation | |---|---| | <5 mIU/L | Excellent insulin sensitivity; optimal for longevity | | 5–7 mIU/L | Good insulin sensitivity; low metabolic risk | | 8–10 mIU/L | Borderline; early insulin resistance likely | | 11–15 mIU/L | Elevated; clinically meaningful insulin resistance | | >15 mIU/L | High; significant metabolic dysfunction; investigate | | >25 mIU/L | Very high; severe insulin resistance or hyperinsulinaemia |

The commonly cited functional medicine target is <7 mIU/L for fasting insulin in a metabolically healthy adult. Values consistently above 10 mIU/L warrant investigation and intervention regardless of what glucose or HbA1c show.

Longevity clinicians including Peter Attia and the work of Jason Fung have both emphasised fasting insulin as arguably the single most important metabolic biomarker — not because of what it directly causes, but because of what it signals: the metabolic environment that drives cardiovascular disease, cancer, neurodegeneration, and accelerated biological ageing. The lab reference range of <25 mIU/L tells you almost nothing useful in this context.

---

HOMA-IR: Pairing Insulin With Glucose

Fasting insulin is most informative when calculated alongside fasting glucose using the HOMA-IR formula (Homeostatic Model Assessment of Insulin Resistance):

HOMA-IR = (Fasting Insulin [mIU/L] × Fasting Glucose [mmol/L]) ÷ 22.5

Australian labs report glucose in mmol/L, so the 22.5 divisor applies directly.

Worked Example

• Fasting insulin: 12 mIU/L
• Fasting glucose: 5.6 mmol/L
• HOMA-IR = (12 × 5.6) ÷ 22.5 = 67.2 ÷ 22.5 = 2.99

Both the glucose and HbA1c on this person's standard panel look entirely unremarkable. HOMA-IR near 3.0 indicates significant insulin resistance requiring intervention.

Why Both Numbers Are Needed

Fasting insulin alone is informative, but HOMA-IR adds precision. A fasting insulin of 10 mIU/L with a glucose of 4.8 mmol/L (HOMA-IR ≈ 2.1) represents a different metabolic picture than the same fasting insulin with a glucose of 6.0 mmol/L (HOMA-IR ≈ 2.7). The glucose-insulin relationship tells more than either value in isolation.

HOMA-IR optimal targets from the research literature:

| HOMA-IR | Interpretation | |---|---| | <1.0 | Optimal insulin sensitivity | | 1.0–1.9 | Early / mild insulin resistance | | 2.0–2.9 | Significant insulin resistance | | >2.9 | Strong insulin resistance; metabolic risk is high |

For a more detailed walkthrough of the HOMA-IR calculation and its clinical applications, see the HOMA-IR guide.

---

What Elevated Fasting Insulin Predicts

The downstream consequences of sustained hyperinsulinaemia extend well beyond type 2 diabetes. Insulin is a growth and storage hormone — in chronic excess, those effects become pathological.

Cardiovascular Disease

Chronically elevated insulin drives the atherogenic lipid triad: elevated triglycerides, low HDL cholesterol, and a shift toward small dense LDL particles. This pattern substantially increases cardiovascular risk independently of LDL-C. Elevated insulin also promotes endothelial dysfunction, increases hepatic VLDL secretion, and contributes to hypertension through sodium retention and sympathetic nervous system activation.

The connection between insulin resistance and cardiovascular risk is one reason longevity-focused clinicians now routinely pair fasting insulin with apolipoprotein B testing — ApoB captures atherogenic particle burden, while fasting insulin captures the metabolic driver producing it.

Type 2 Diabetes

The progression from insulin resistance to type 2 diabetes is, at its core, a story of beta cell failure under the burden of sustained hyperinsulinaemia. Elevated fasting insulin is the earliest detectable signal in this trajectory — preceding impaired fasting glucose by a decade or more in many individuals. Identifying and addressing it at this stage is the difference between prevention and management.

Polycystic Ovarian Syndrome (PCOS)

Insulin resistance is a core pathophysiological driver of PCOS in the majority of affected women, including lean women without obvious metabolic syndrome. Elevated insulin amplifies LH-driven androgen secretion from the ovaries and suppresses SHBG, increasing free androgen levels. Fasting insulin and HOMA-IR are essential components of any comprehensive PCOS investigation — not optional additions.

Non-Alcoholic Fatty Liver Disease (NAFLD)

Insulin resistance promotes de novo lipogenesis in the liver and impairs hepatic fat export via VLDL. Fasting insulin tracks liver fat accumulation closely and often rises before liver enzymes (ALT, AST) move on a standard panel. Fatty liver detected on imaging frequently correlates with fasting insulin values above 12–15 mIU/L.

Certain Cancers

The cancer link is less familiar but mechanistically coherent. Insulin stimulates cell proliferation through IGF-1 receptor cross-activation and direct insulin receptor signalling. Observational data consistently associate hyperinsulinaemia and insulin resistance with increased risk of colorectal, breast, endometrial, and pancreatic cancers. This is an area of active research rather than settled clinical guidance, but it reinforces the case for treating elevated fasting insulin as a serious metabolic signal rather than a laboratory curiosity.

---

Getting Fasting Insulin Tested in Australia

Medicare Item 66561

Medicare rebates fasting insulin testing under Item 66561, which covers insulin measurement in specific clinical contexts including assessment of hypoglycaemia and investigation of insulin secretory function. A GP can order this test with a Medicare rebate — but many do not, either because they are unfamiliar with its utility in metabolic screening or because clinical protocols do not include it in standard panels.

If your GP is open to it: ask for fasting insulin alongside your next fasting glucose and lipid panel. Frame it as metabolic screening, particularly if you have risk factors including central obesity, elevated triglycerides, family history of type 2 diabetes, PCOS, or fatty liver. The rebated gap cost is minimal.

Private Pathology

If you are self-directing, fasting insulin is available through major private pathology providers without a GP referral:

• Sonic Healthcare (including Laverty, Sullivan Nicolaides, Clinical Labs) — fasting insulin available as a standalone add-on
• Healthscope Pathology — available on request
• Direct-to-consumer services (Adora Diagnostics, Lyf Healthcare, and similar) — typically bundle fasting insulin with glucose and lipid panels in metabolic health packages

Out-of-pocket costs for fasting insulin through private pathology are typically $20–$35 depending on the provider and whether it is bundled. Adding it to an existing panel on a private (non-Medicare) basis is at the lower end of this range. Fasting glucose, if not already known, adds negligible cost and is often included in the same draw.

Sample Requirements

• Minimum 8–10 hour overnight fast; 10–12 hours is ideal
• Morning collection is standard
• Avoid intense exercise the evening before — this can temporarily suppress fasting insulin and produce an artificially low result
• Standard serum tube (gold top); no special transport requirements

---

How to Lower Fasting Insulin

The evidence base for reducing fasting insulin through lifestyle intervention is extensive and consistent. These are not marginal effects — sustained lifestyle changes can halve fasting insulin within weeks to months in many individuals.

Dietary Changes

Reduce ultra-processed food and refined carbohydrates. Foods with high glycaemic load — refined grains, added sugars, sweetened beverages — drive the largest acute insulin responses and contribute to chronic hyperinsulinaemia through progressive receptor downregulation and beta cell stress. Replacing these with fibre-rich whole foods is the single highest-leverage dietary change.

Low-glycaemic eating patterns. Mediterranean, low-carbohydrate, and whole-food-based diets all consistently reduce fasting insulin in randomised trials. The mechanism is straightforward: lower postprandial glucose excursions demand less insulin, and foods that naturally stimulate GLP-1 further slow gastric emptying and reduce the insulin burden of each meal. Soluble fibre (oats, legumes, psyllium) and resistant starch slow digestion and blunt the insulin response of mixed meals.

Reduce fructose intake specifically. Fructose is metabolised almost exclusively in the liver, promoting de novo lipogenesis and hepatic insulin resistance at a disproportionate rate relative to its caloric contribution. Liquid fructose — soft drinks, fruit juices, energy drinks — is particularly problematic.

Time-Restricted Eating

Time-restricted eating (TRE) — compressing caloric intake into a 6–10 hour daily window — reduces fasting insulin through several mechanisms: it extends the overnight fasting period during which insulin remains low, reduces meal frequency and associated insulin pulses, and tends to reduce total caloric intake without active restriction. Trials comparing TRE to isocaloric feeding consistently show superior improvements in fasting insulin even with caloric intake held constant.

A 16:8 eating window (16 hours fasting, 8-hour eating window) is the most studied and practically sustainable approach. Benefits on fasting insulin typically become measurable within 4–6 weeks.

Resistance Training

Skeletal muscle is the primary site of insulin-stimulated glucose disposal. Resistance training increases GLUT4 transporter density in muscle fibres, improving insulin-stimulated glucose uptake for 24–48 hours per session. Three to four sessions per week of compound resistance exercises produces consistent reductions in fasting insulin across the literature — independent of weight loss.

The mechanism extends beyond glucose disposal: muscle tissue functions as an endocrine organ, secreting myokines that improve hepatic insulin sensitivity and reduce visceral adiposity over time.

Aerobic Exercise

Aerobic exercise improves insulin sensitivity through distinct mechanisms — increasing mitochondrial density, reducing visceral fat, and improving hepatic glucose regulation. Combining aerobic and resistance training produces the largest effects. Post-meal walks (10–15 minutes) are a particularly accessible intervention that meaningfully blunts postprandial insulin spikes even in the absence of a formal exercise programme.

Sleep and Stress

A single night of significantly disrupted sleep reduces insulin sensitivity measurably the following morning. Chronic short sleep (<6 hours) is associated with fasting insulin values 20–30% higher than in matched controls sleeping 7–8 hours. Cortisol — elevated by both sleep deprivation and psychological stress — is a counter-regulatory hormone that directly antagonises insulin signalling. Addressing sleep quality and cortisol burden is not peripheral to metabolic health; it is central to it.

---

Fasting Insulin in the Longevity Context

The interest in fasting insulin among longevity researchers is not incidental. Chronic hyperinsulinaemia accelerates several of the major pathways implicated in biological ageing: mTOR activation, IGF-1 signalling, and inflammatory cytokine production all rise in states of insulin excess. Conversely, lower fasting insulin — within the optimal range — is consistently associated with lower all-cause mortality in prospective cohorts.

Peter Attia has described fasting insulin as among the tests he most wants universally adopted in preventive medicine, alongside HOMA-IR and ApoB. Jason Fung's work on therapeutic fasting as an insulin-lowering intervention has brought the concept of hyperinsulinaemia as a primary driver — rather than a downstream consequence — to a wider clinical audience.

The practical implication is that fasting insulin is worth tracking even when all other metabolic markers appear normal, particularly for anyone interested in optimising healthspan rather than simply avoiding overt disease. Broader peptide and metabolic research into interventions that modulate insulin signalling consistently identifies fasting insulin as a central outcome variable — reflecting its status as one of the most proximate markers of metabolic function available in routine clinical practice.

---

Interpreting Your Result: A Practical Framework

Step 1 — Get the right number. Confirm your result is in mIU/L (also reported as µIU/mL — equivalent units). Apply the functional medicine targets (<7 mIU/L optimal; concerning above 10 mIU/L), not the lab reference range of <25 mIU/L.

Step 2 — Calculate HOMA-IR. Pair fasting insulin with your fasting glucose from the same draw: (insulin × glucose) ÷ 22.5. A result above 2.0 warrants attention; above 2.9 warrants action.

Step 3 — Check the lipid context. Elevated fasting insulin alongside elevated triglycerides (>1.7 mmol/L) and low HDL strongly suggests metabolic syndrome with hepatic insulin resistance driving excess VLDL production. This combination also points toward elevated ApoB — it is worth checking.

Step 4 — Identify drivers. High fasting insulin is a downstream result. The most common drivers are visceral adiposity, physical inactivity, poor sleep, high refined-carbohydrate intake, and chronic stress. Addressing these in combination — rather than sequentially — produces the fastest improvements.

Step 5 — Track trajectory. Retest every 3 months when actively working to improve insulin sensitivity. A consistent downward trend in fasting insulin is a meaningful signal that interventions are working, regardless of where absolute values started.

---

Key Takeaways

• Fasting insulin rises during insulin resistance years before fasting glucose or HbA1c move — it is the earliest available routine blood marker of metabolic dysfunction
• The standard lab reference range (<25 mIU/L) is not a clinical target; functional medicine optimal is <7 mIU/L, with values above 10 mIU/L indicating meaningful insulin resistance
• Pair fasting insulin with fasting glucose to calculate HOMA-IR: (insulin × glucose) ÷ 22.5; below 1.0 is optimal, above 2.9 indicates significant resistance
• Elevated fasting insulin predicts cardiovascular disease, type 2 diabetes, PCOS, NAFLD, and certain cancers — often well before conventional markers flag anything
• Medicare Item 66561 covers fasting insulin testing via GP; private pathology costs $20–$35 as a standalone test
• The most effective interventions are dietary quality (reducing ultra-processed food and refined carbohydrate), time-restricted eating, resistance training, and sleep optimisation
• Fasting insulin is one of the cheapest, most actionable metabolic tests available — the barrier to ordering it is convention, not science